[HTML][HTML] Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK …
J Wolf, IJ Oh, MR Migliorino, R Dziadziuszko, A Wrona… - ESMO open, 2022 - Elsevier
Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive …
J Wolf, Å Helland, IJ Oh, MR Migliorino… - ESMO Open, 2022 - europepmc.org
Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
[HTML][HTML] Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK …
J Wolf, Å Helland, IJ Oh, MR Migliorino… - ESMO Open, 2022 - esmoopen.com
Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive …
J Wolf, A Helland, IJ Oh, MR Migliorino… - ESMO …, 2022 - kups.ub.uni-koeln.de
Background: At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
[HTML][HTML] Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK …
J Wolf, Å Helland, IJ Oh, MR Migliorino… - ESMO Open, 2022 - ncbi.nlm.nih.gov
Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
[PDF][PDF] Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK …
J Wolf, Å Helland, IJ Oh, MR Migliorino, R Dziadziuszko… - ppm.gumed.edu.pl
Background: At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive …
J Wolf, Å Helland, IJ Oh, MR Migliorino, R Dziadziuszko… - 2022 - pubmed.ncbi.nlm.nih.gov
Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive …
J Wolf, A Helland, O IJ, MR Migliorino, R Dziadziuszko… - ESMO OPEN, 2022 - iris.unito.it
Background: At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
[PDF][PDF] Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK …
J Wolf, Å Helland, IJ Oh, MR Migliorino, R Dziadziuszko… - core.ac.uk
Background: At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive …
J Wolf, Å Helland, IJ Oh, MR Migliorino, R Dziadziuszko… - ESMO Open, 2022 - duo.uio.no
Background At the primary data cut-off, the ALUR study demonstrated significantly improved
progression-free survival (PFS) and central nervous system (CNS) objective response rate …
progression-free survival (PFS) and central nervous system (CNS) objective response rate …